Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659880 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL1713616 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL12316010 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL27626477 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL1713614 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL739575 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL1263214 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL523698 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL522714 | 0.90 | KMT2A (0.81) | KMT2AMAPTMAPK1ALOX15POLB | |
| SCHEMBL522715 | 0.90 | KMT2A (0.81) | KMT2AMAPTMAPK1ALOX15POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| CN-101945655-A | 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators | GLAXO GROUP LTD | 2011-01-12 | — | — | CN | disclosed |
| US-20100292295-A1 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-18 | — | — | US | disclosed |
| EP-2231153-A2 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009077559-A2 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292295-A1 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | P2RX3, P2RX6, P2RX7 | KMT2A 3268/4885MAPT 4861/4885MAPK1 1058/4885 |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | PSEN1, PRNP, PSEN2 | KMT2A 3040/4885MAPT 4/4885MAPK1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.